Prax­is touts topline da­ta for epilep­sy drug in first of four read­outs

In Jan­u­ary, Prax­is priced a $150 mil­lion pub­lic stock of­fer­ing and promised four da­ta read­outs. And on Tues­day morn­ing, the first topline da­ta dropped in a small up­date from its Phase 2a study in pho­to-sen­si­tive epilep­sy pa­tients, with the com­pa­ny say­ing that the da­ta are pos­i­tive enough to move its drug in­to fo­cal epilep­sy.

The study mea­sured elec­troen­cephalo­gram sig­na­tures (elec­tri­cal ac­tiv­i­ty) in the brain af­ter in­ter­mit­tent phot­ic stim­u­la­tion, a type of vi­su­al stim­u­la­tion, which is used as an in­di­ca­tor of an­ti-seizure ef­fi­ca­cy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER